- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S R&D Investor Call Transcript
Hello, and welcome to the Novo Nordisk A/S R&D Investor Call. (Operator Instructions) I'll now hand the floor to our speakers, please begin your meeting.
/- -
Thank you. Welcome to the Novo Nordisk Investor Call in connection with ADA. My name is Karsten Knudsen, CFO of Novo Nordisk. And with me today, I have Marcus Schindler, Chief Scientific Officer and EVP of Research and Early Development; as well as Martin Lange, EVP of Global Development. At today's call, there may be forward-looking statements and projections around the future, which by their very nature, clearly, inherently are uncertain and where outcomes may turn out differently.
As usual, we anchor our communications around our strategic aspirations 2025, which are covering our strategy execution as a company. Today's focus is purely on the quadrant denoted innovation and therapeutic focus, where we'll be covering our progress within raising the innovation
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |